Journal ArticleDOI
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry André,Armand de Gramont,Dewi Vernerey,Benoist Chibaudel,Franck Bonnetain,Annemilaï Tijeras-Raballand,Aurelie Scriva,Tamas Hickish,Josep Tabernero,Jean-Luc Van Laethem,Maria Banzi,E. Maartense,Einat Shacham Shmueli,Göran Carlsson,Werner Scheithauer,Demetris Papamichael,Marcus Möehler,Stefania Landolfi,Pieter Demetter,Soudhir Colote,Christophe Tournigand,Christophe Louvet,Alex Duval,Jean François Fléjou,Aimery de Gramont +24 more
Reads0
Chats0
TLDR
The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer, and updated results support the use of FOLFOX in Patients with stage III disease, including those with dMMR or BRAF mutation.Abstract:
Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results After a median follow-up of 9.5 years, 10-year OS rates in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX4) arms were 67.1% versus 71.7% (hazard ratio [HR], 0.85; P = .043) in the whole population, 79.5% versus 78.4% for stage II (HR, 1.00; P = .980), and 59.0% versus 67.1% for stage III (HR, 0.80; P = .016) disease. Ninety-five patients (9...read more
Citations
More filters
Journal ArticleDOI
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Jeanne Tie,Yuxuan Wang,Cristian Tomasetti,Cristian Tomasetti,Lu Li,Simeon Springer,Isaac Kinde,Natalie Silliman,Mark Tacey,Hui-Li Wong,Hui-Li Wong,Michael Christie,Michael Christie,Suzanne Kosmider,Iain Skinner,Rachel Wong,Rachel Wong,Malcolm Steel,Ben Tran,Jayesh Desai,Jayesh Desai,Ian T. Jones,Ian T. Jones,Andrew Haydon,Theresa M. Hayes,Timothy J. Price,Robert L. Strausberg,Luis A. Diaz,Nickolas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Peter Gibbs +31 more
TL;DR: It is shown that the presence of circulating tumor DNA in a patient’s blood after surgery is a sign of persistent tumor and a greatly increased risk of relapse, suggesting that this group of patients may require chemotherapy to prevent recurrence.
Journal ArticleDOI
Comprehensive review of targeted therapy for colorectal cancer
TL;DR: This review provides an overview of existing CRC-targeted agents and their underlying mechanisms, as well as a discussion of their limitations and future trends.
Journal ArticleDOI
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey,Alberto Sobrero,Anthony F. Shields,Takayuki Yoshino,James Paul,Julien Taieb,John Souglakos,Qian Shi,Rachel Kerr,Roberto Labianca,Jeffrey A. Meyerhardt,Dewi Vernerey,Takeharu Yamanaka,Ioannis Boukovinas,Jeffrey P. Meyers,Lindsay A. Renfro,Donna Niedzwiecki,Donna Niedzwiecki,Toshiaki Watanabe,Valter Torri,Valter Torri,Mark P Saunders,Daniel J. Sargent,Thierry André,Timothy Iveson +24 more
TL;DR: Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population.
Journal ArticleDOI
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Myriam Chalabi,Lorenzo F. Fanchi,Krijn K. Dijkstra,José G van den Berg,Arend G. J. Aalbers,Karolina Sikorska,Marta Lopez-Yurda,Cecile Grootscholten,Geerard L. Beets,Geerard L. Beets,Petur Snaebjornsson,Monique Maas,Marjolijn Mertz,Vivien Veninga,Gergana Bounova,Annegien Broeks,Regina G. H. Beets-Tan,Regina G. H. Beets-Tan,Thomas R de Wijkerslooth,Anja U. van Lent,Hendrik A Marsman,Elvira Nuijten,Niels F. M. Kok,Maria Kuiper,Wieke H M Verbeek,Marleen Kok,Monique E. van Leerdam,Ton N. Schumacher,Emile E. Voest,John B. A. G. Haanen +29 more
TL;DR: The data indicate that neoadjuvant immunotherapy may have the potential to become the standard of care for a defined group of colon cancer patients when validated in larger studies with at least 3 years of disease-free survival data.
Journal ArticleDOI
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis
Fausto Petrelli,Gianluca Tomasello,Karen Borgonovo,Michele Ghidini,Luca Turati,Pierpaolo Dallera,Rodolfo Passalacqua,Giovanni Sgroi,Sandro Barni +8 more
TL;DR: CC side should be acknowledged as a criterion for establishing prognosis in all stages of disease, and should represent a stratification factor for future adjuvant studies.
References
More filters
Journal ArticleDOI
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
TL;DR: In this article, an easily interpretable index of predictive discrimination as well as methods for assessing calibration of predicted survival probabilities are discussed, which are particularly needed for binary, ordinal, and time-to-event outcomes.
Book ChapterDOI
Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors
TL;DR: An easily interpretable index of predictive discrimination as well as methods for assessing calibration of predicted survival probabilities are discussed, applicable to all regression models, but are particularly needed for binary, ordinal, and time-to-event outcomes.
Tutorial in biostatistics multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
Kerry L. Lee,Daniel B. Mark +1 more
TL;DR: An easily interpretable index of predictive discrimination as well as methods for assessing calibration of predicted survival probabilities are discussed, which are applicable to all regression models, but are particularly needed for binary, ordinal, and time-to-event outcomes.
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Journal ArticleDOI
A note on quantifying follow-up in studies of failure time
Michael Schemper,Terry L. Smith +1 more
TL;DR: It is shown that values of median follow-up may differ substantially depending on the method used, and standard analytical methods for survival data, such as the log-rank test 121, the generalized Wilcoxon test, or the proportional hazards model 141, estimate average effects for the observed response times and test those effects for significance.
Related Papers (5)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
The consensus molecular subtypes of colorectal cancer
Justin Guinney,Rodrigo Dienstmann,Rodrigo Dienstmann,Xingwu Wang,Xingwu Wang,Aurélien de Reyniès,Andreas Schlicker,Charlotte Soneson,Laetitia Marisa,Paul Roepman,Gift Nyamundanda,Paolo Angelino,Brian M. Bot,Jeffrey S. Morris,Iris Simon,Sarah Gerster,Evelyn Fessler,Felipe De Sousa E Melo,Edoardo Missiaglia,Hena R. Ramay,David Barras,Krisztian Homicsko,Dipen M. Maru,Ganiraju C. Manyam,Bradley M. Broom,Valérie Boige,Beatriz Perez-Villamil,Ted Laderas,Ramon Salazar,Joe W. Gray,Douglas Hanahan,Josep Tabernero,René Bernards,Stephen H. Friend,Pierre Laurent-Puig,Jan Paul Medema,Anguraj Sadanandam,Lodewyk F. A. Wessels,Mauro Delorenzi,Mauro Delorenzi,Scott Kopetz,Louis Vermeulen,Sabine Tejpar +42 more